A Polygenic Methylation Prediction Model Associated with Response to Chemotherapy in Epithelial Ovarian Cancer

Overview

Journal Mol Ther Oncolytics

Publisher Cell Press

Date 2021 Mar 19

PMID 33738340

Citations 6

Authors

Lanbo Zhao

Sijia Ma

Linconghua Wang

Yiran Wang

Xue Feng

Dongxin Liang

Lu Han

Min Li

Qiling Li

Affiliations

Soon will be listed here.

Abstract

To identify potential aberrantly differentially methylated genes (DMGs) correlated with chemotherapy response (CR) and establish a polygenic methylation prediction model of CR in epithelial ovarian cancer (EOC), we accessed 177 (47 chemo-sensitive and 130 chemo-resistant) samples corresponding to three DNA-methylation microarray datasets from the Gene Expression Omnibus and 306 (290 chemo-sensitive and 16 chemo-resistant) samples from The Cancer Genome Atlas (TCGA) database. DMGs associated with chemotherapy sensitivity and chemotherapy resistance were identified by several packages of R software. Pathway enrichment and protein-protein interaction (PPI) network analyses were constructed by Metascape software. The key genes containing mRNA expressions associated with methylation levels were validated from the expression dataset by the GEO2R platform. The determination of the prognostic significance of key genes was performed by the Kaplan-Meier plotter database. The key genes-based polygenic methylation prediction model was established by binary logistic regression. Among accessed 483 samples, 457 (182 hypermethylated and 275 hypomethylated) DMGs correlated with chemo resistance. Twenty-nine hub genes were identified and further validated. Three genes, anterior gradient 2 (AGR2), heat shock-related 70-kDa protein 2 (HSPA2), and acetyltransferase 2 (ACAT2), showed a significantly negative correlation between their methylation levels and mRNA expressions, which also corresponded to prognostic significance. A polygenic methylation prediction model (0.5253 cutoff value) was established and validated with 0.659 sensitivity and 0.911 specificity.

Citing Articles

HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.

Ma S, Wang J, Cui Z, Yang X, Cui X, Li X Sci Rep. 2024; 14(1):3870.

PMID: 38365849 PMC: 10873328. DOI: 10.1038/s41598-024-53854-y.

Predictive Value of Machine Learning for Platinum Chemotherapy Responses in Ovarian Cancer: Systematic Review and Meta-Analysis.

Wang Q, Chang Z, Liu X, Wang Y, Feng C, Ping Y J Med Internet Res. 2024; 26:e48527.

PMID: 38252469 PMC: 10845031. DOI: 10.2196/48527.

High-expressed ACAT2 predicted the poor prognosis of platinum-resistant epithelial ovarian cancer.

Wang J, Yang Z, Bai H, Zhao L, Ji J, Bin Y Diagn Pathol. 2024; 19(1):7.

PMID: 38178203 PMC: 10768435. DOI: 10.1186/s13000-023-01435-4.

A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer.

Mo J, Ruan S, Yang B, Jin Y, Liu K, Luo X J Zhejiang Univ Sci B. 2023; 24(1):64-77.

PMID: 36632751 PMC: 9837372. DOI: 10.1631/jzus.B2200272.

The Methylation Game: Epigenetic and Epitranscriptomic Dynamics of 5-Methylcytosine.

Alagia A, Gullerova M Front Cell Dev Biol. 2022; 10:915685.

PMID: 35721489 PMC: 9204050. DOI: 10.3389/fcell.2022.915685.

References

Cacan E . Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells. J Chemother. 2017; 29(3):173-178. DOI: 10.1080/1120009X.2016.1277007. View

Alves M, Melo N, Barros-Filho M, Soares do Amaral N, Silva F, Baiocchi Neto G . Downregulation of AGR2, p21, and cyclin D and alterations in p53 function were associated with tumor progression and chemotherapy resistance in epithelial ovarian carcinoma. Cancer Med. 2018; 7(7):3188-3199. PMC: 6051166. DOI: 10.1002/cam4.1530. View

Chang X, Monitto C, Demokan S, Kim M, Chang S, Zhong X . Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res. 2010; 70(7):2870-9. PMC: 2849007. DOI: 10.1158/0008-5472.CAN-09-3427. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Pruszynski M, Koumarianou E, Vaidyanathan G, Revets H, Devoogdt N, Lahoutte T . Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med. 2014; 55(4):650-6. PMC: 4157601. DOI: 10.2967/jnumed.113.127100. View

Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Oza A . Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int J Gynecol Cancer. 2009; 19 Suppl 2:S44-8. DOI: 10.1111/IGC.0b013e3181bf7fb8. View

Bergstrom J, Berg K, Rodriguez-Pineiro A, Stecher B, Johansson M, Hansson G . AGR2, an endoplasmic reticulum protein, is secreted into the gastrointestinal mucus. PLoS One. 2014; 9(8):e104186. PMC: 4128659. DOI: 10.1371/journal.pone.0104186. View

Tomar T, Alkema N, Schreuder L, Meersma G, De Meyer T, Van Criekinge W . Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Med. 2017; 15(1):116. PMC: 5481993. DOI: 10.1186/s12916-017-0870-0. View

Taylor K, Eskander R . PARP Inhibitors in Epithelial Ovarian Cancer. Recent Pat Anticancer Drug Discov. 2017; 13(2):145-158. DOI: 10.2174/1574892813666171204094822. View

10.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

11.

Zhao Z, Lu J, Han L, Wang X, Man Q, Liu S . Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma. Tumour Biol. 2015; 37(6):8121-30. DOI: 10.1007/s13277-015-4720-4. View

12.

Friedlander M, Stockler M, Butow P, King M, McAlpine J, Tinker A . Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?. J Clin Oncol. 2013; 31(18):2362. DOI: 10.1200/JCO.2012.47.7927. View

13.

Li M, Balch C, Montgomery J, Jeong M, Chung J, Yan P . Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2009; 2:34. PMC: 2712480. DOI: 10.1186/1755-8794-2-34. View

14.

Gonzalez Bosquet J, Newtson A, Chung R, Thiel K, Ginader T, Goodheart M . Prediction of chemo-response in serous ovarian cancer. Mol Cancer. 2016; 15(1):66. PMC: 5070116. DOI: 10.1186/s12943-016-0548-9. View

15.

Tian H, Yan L, Xiao-Fei L, Hai-Yan S, Juan C, Shan K . Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer. Clin Epigenetics. 2019; 11(1):153. PMC: 6822346. DOI: 10.1186/s13148-019-0748-4. View

16.

Zhai L, Xie Q, Zhou C, Huang D, Tang Z, Ju T . Overexpressed HSPA2 correlates with tumor angiogenesis and unfavorable prognosis in pancreatic carcinoma. Pancreatology. 2017; 17(3):457-463. DOI: 10.1016/j.pan.2017.04.007. View

17.

Sevier C, Kaiser C . Formation and transfer of disulphide bonds in living cells. Nat Rev Mol Cell Biol. 2002; 3(11):836-47. DOI: 10.1038/nrm954. View

18.

Alberts D . Treatment of refractory and recurrent ovarian cancer. Semin Oncol. 1999; 26(1 Suppl 1):8-14. View

19.

Natanzon Y, Goode E, Cunningham J . Epigenetics in ovarian cancer. Semin Cancer Biol. 2017; 51:160-169. PMC: 5976557. DOI: 10.1016/j.semcancer.2017.08.003. View

20.

Wang J, Zhong J, Chen G, Li M, Wu F, Pan Y . ClusterViz: A Cytoscape APP for Cluster Analysis of Biological Network. IEEE/ACM Trans Comput Biol Bioinform. 2015; 12(4):815-22. DOI: 10.1109/TCBB.2014.2361348. View